Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma

被引：10

作者：

Carloni, Riccardo ^{[1
,2
]}

Sabbioni, Simone ^{[1
,2
]}

Rizzo, Alessandro ^{[3
,6
]}

Ricci, Angela Dalia ^{[4
]}

Palloni, Andrea ^{[1
,2
]}

Petrarota, Cataldo ^{[3
]}

Cusmai, Antonio ^{[3
]}

Tavolari, Simona ^{[1
,2
]}

Gadaleta-Caldarola, Gennaro ^{[5
]}

Brandi, Giovanni ^{[1
,2
]}

机构：

[1] Univ Bologna, Dept Specialized Expt & Diagnost Med, Bologna, Italy

[2] IRCCS Azienda Osped Univ Bologna, Div Med Oncol, Bologna, Italy

[3] IRCCS Ist Tumori Giovanni Paolo II, Struttura Semplice Dipartimentale Oncol Med Presa, Bari, Italy

[4] Saverio Bellis Res Hosp, Natl Inst Gastroenterol, Med Oncol Unit, Bari, Italy

[5] Osped Mons AR Dimiccoli, Unita Operativa Complessa Oncol Med, Barletta, Italy

[6] IRCCS Ist Tumori Giovanni Paolo II, Struttura Semplice Dipartimentale Oncol Med Presa, Viale Orazio Flacco 65, I-70124 Bari, Italy

来源：

JOURNAL OF HEPATOCELLULAR CARCINOMA | 2023年 / 10卷

关键词：

hepatocellular carcinoma; VEGF; PD-1; tislelizumab; atezolizumab; durvalumab; ATEZOLIZUMAB PLUS BEVACIZUMAB; INFILTRATING T-CELLS; PHASE-I TRIAL; CHILD-PUGH; OPEN-LABEL; SAFETY; SORAFENIB; LANDSCAPE; NIVOLUMAB; VACCINE;

D O I：

10.2147/JHC.S390963

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hepatocellular carcinoma (HCC) is the fourth most frequent cause of cancer-related death worldwide. HCC frequently presents as advanced disease at diagnosis, and disease relapse following radical surgery is frequent. In recent years, immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced HCC, particularly with the introduction of atezolizumab/ bevacizumab as the new standard of care for first-line treatment. Recently, dual immune checkpoint blockade with durvalumab plus tremelimumab has also emerged as an effective first-line treatment for advanced HCC and most of the research is currently focused on developing combination treatments based mainly on ICIs. In this review, we will discuss the rationale and ongoing clinical trials of immune-based combination therapies for the treatment of advanced HCC, also focusing on new immunotherapy strategies such as chimeric antigen receptor T cells (CAR-T) and anti-cancer vaccines.

引用

页码：1445 / 1463

页数：19

共 119 条

[1] Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma [J].

Abou-Alfa, G. K. ;

Meyer, T. ;

Cheng, A. -L. ;

El-Khoueiry, A. B. ;

Rimassa, L. ;

Ryoo, B. -Y. ;

Cicin, I. ;

Merle, P. ;

Chen, Y. H. ;

Park, J. -W. ;

Blanc, J. -F. ;

Bolondi, L. ;

Klumpen, H. -J. ;

Chan, S. L. ;

Zagonel, V. ;

Pressiani, T. ;

Ryu, M. -H. ;

Venook, A. P. ;

Hessel, C. ;

Borgman-Hagey, A. E. ;

Schwab, G. ;

Kelley, R. K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) :54-63

[2]

Abou-Alfa GK, 2022, NEJM EVID, V1, DOI [10.1056/evidoa2100070, 10.1056/EVIDoa2100070]

[3]

Academic and Community Cancer Research United, 2022, A phase II study of nivolumab + ipilimumab in advanced HCC patients who have progressed on first line atezolizumab + bevacizumab

[4] The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer [J].

Affo, Silvia ;

Yu, Le-Xing ;

Schwabe, Robert F. .

ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 12, 2017, 12 :153-186

[5] IL27 Signaling Serves as an Immunologic Checkpoint for Innate Cytotoxic Cells to Promote Hepatocellular Carcinoma [J].

Aghayev, Turan ;

Mazitova, Aleksandra M. ;

Fang, Jennifer R. ;

Peshkova, Iuliia O. ;

Rausch, Matthew ;

Hung, Manhsih ;

White, Kerry F. ;

Masia, Ricard ;

Titerina, Elizaveta K. ;

Fatkhullina, Aliia R. ;

Cousineau, Isabelle ;

Turcotte, Simon ;

Zhigarev, Dmitry ;

Marchenko, Anastasiia ;

Khoziainova, Svetlana ;

Makhov, Petr ;

Tan, Yin Fei ;

Kossenkov, Andrew, V ;

Wiest, David L. ;

Stagg, John ;

Wang, Xin Wei ;

Campbell, Kerry S. ;

Dzutsev, Amiran K. ;

Trinchieri, Giorgio ;

Hill, Jonathan A. ;

Grivennikov, Sergei I. ;

Koltsova, Ekaterina K. .

CANCER DISCOVERY, 2022, 12 (08) :1960-1983

[6] TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy [J].

Akalu, Yemsratch T. ;

Rothlin, Carla V. ;

Ghosh, Sourav .

IMMUNOLOGICAL REVIEWS, 2017, 276 (01) :165-177

[7]

AstraZeneca, 2022, A Phase III, randomized, open-label, sponsor-blinded, multicenter study of durvalumab in combination with tremelimumab lenvatinib given concurrently with TACE Compared to TACE alone in patients with locoregional hepatocellular carcinoma (EMERALD-3)

[8] Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination [J].

Boutros, Celine ;

Tarhini, Ahmad ;

Routier, Emilie ;

Lambotte, Olivier ;

Ladurie, Francois Leroy ;

Carbonnel, Franck ;

Izzeddine, Hassane ;

Marabelle, Aurelien ;

Champiat, Stephane ;

Berdelou, Armandine ;

Lanoy, Emilie ;

Texier, Matthieu ;

Libenciuc, Cristina ;

Eggermont, Alexander M. M. ;

Soria, Jean-Charles ;

Mateus, Christine ;

Robert, Caroline .

NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (08) :473-486

[9] Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227 [J].

Brahmer, Julie R. ;

Lee, Jong-Seok ;

Ciuleanu, Tudor-Eliade ;

Bernabe Caro, Reyes ;

Nishio, Makoto ;

Urban, Laszlo ;

Audigier-Valette, Clarisse ;

Lupinacci, Lorena ;

Sangha, Randeep ;

Pluzanski, Adam ;

Burgers, Jacobus ;

Mahave, Mauricio ;

Ahmed, Samreen ;

Schoenfeld, Adam J. ;

Paz-Ares, Luis G. ;

Reck, Martin ;

Borghaei, Hossein ;

O'Byrne, Kenneth J. ;

Gupta, Ravi G. ;

Bushong, Judith ;

Li, Li ;

Blum, Steven I. ;

Eccles, Laura J. ;

Ramalingam, Suresh S. .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (06) :1200-+

[10]

Bristol-Myers Squibb, 2022, A phase 2, randomized, open-label study of relatlimab in combination with nivolumab in participants with advanced hepatocellular carcinoma who are naive to IO therapy but progressed on tyrosine kinase inhibitors (RELATIVITY-073)

← 1 2 3 4 5 6 7 8 9 10 →